Sygnis

Sygnis Days Sales Outstanding

The Days Sales Outstanding (DSO) of Sygnis (SYG.WA) as of Nov 6, 2026 is 207.22. In the previous year, Days Sales Outstanding (DSO) was 25.59 — a change of 709.67% (higher).

Days Sales Outstanding

207.22

YoY

709.67%

Last updated:

Days Sales Outstanding (DSO) of Sygnis is 2025 207.22 . Days Sales Outstanding (DSO) of Sygnis was 2024 25.59 . It decreases by 709.67% higher compared to the previous year.

The Sygnis Days Sales Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Sales Outstanding
Date
Days Sales Outstanding
Jan 1, 2017
0.62 PLN
Jan 1, 2018
6.05 PLN
Jan 1, 2020
13.07 PLN
Jan 1, 2021
278.56 PLN
Jan 1, 2022
35.62 PLN
Jan 1, 2023
16.93 PLN
Jan 1, 2024
25.59 PLN
Jan 1, 2025
207.22 PLN
The Sygnis Days Sales Outstanding history
YEARDays Sales OutstandingYoY
207.22+709.67%
25.59+51.21%
16.93-52.49%
35.62-87.21%
278.56+2,030.90%
13.07+116.01%
6.05+870.01%
0.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sygnis Stock analysis

What does Sygnis do? Sygnis SA generates revenue through its research and development services across four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence focuses on bioprinting organs to prevent transplant shortages and creating bionic models for drug testing. Nanotechnology applies photoelectron spectroscopy and atomic force microscopy solutions to consumer products. Power Engineering develops energy storage methods for renewable energy sources. New Incremental Technologies specializes in 3D printing solutions. The company collaborates with over 85 specialists including physicists, mechatronics, chemists, engineers, designers, and sociologists to execute multiple projects. Clients for Sygnis SA's services include organizations requiring advanced research in bioprinting, nanotechnology applications, energy storage, and 3D printing solutions. The firm serves sectors such as healthcare, technology, and renewable energy through its specialized R&D segments. Projects are executed by its team of 85 specialists working across the four business areas. Sygnis SA's revenue streams are derived from contracts with clients seeking innovative R&D in organ bioprinting, bionic drug testing models, photoelectron spectroscopy applications, energy storage systems, and 3D printing technologies. The company's business model relies on delivering specialized research services to clients across healthcare, technology, and renewable energy sectors through its four distinct R&D segments. Sygnis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sygnis stock

Days Sales Outstanding (DSO) of Sygnis is 207.22 in 2025.

Days Sales Outstanding (DSO) of Sygnis changed from 25.59 to 207.22, representing a 709.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Sales Outstanding (DSO) Sygnis since 2006 – with annual values, charts, and detailed analysis.

DSO measures the average number of days it takes to collect payment after a sale. Lower DSO indicates faster cash collection.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Sales Outstanding (DSO)'s Sygnis with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Sales Outstanding (DSO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Sales Outstanding (DSO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Sygnis

All Key Metrics — Sygnis